Drug discovery: A jump-start for electroceuticals
Name
Boyden_Drug discovery.pdf
Size
123.86 KB
Format
Adobe PDF
Checksum (MD5)
68aeeebd4e0fa2462382beb52e5e9761
Author(s)
Famm, Kristoffer
Litt, Brian
Tracey, Kevin J.
Boyden, Edward Stuart
Slaoui, Moncef
Date Issued
April 2013
Journal
Nature
Publisher
Nature Publishing Group
Citation
Famm, Kristoffer, Brian Litt, Kevin J. Tracey, Edward S. Boyden, and Moncef Slaoui. “Drug Discovery: A Jump-Start for Electroceuticals.” Nature 496, no. 7444 (April 10, 2013): 159–161.
Version
Author's final manuscript
Abstract
Imagine a day when electrical impulses are a mainstay of medical treatment. Your clinician will administer electroceuticals that target individual nerve fibres or specific brain circuits to treat an array of conditions. These will modulate the neural impulses that control the body, repair lost function and reinstate a healthy balance. They could coax insulin from islet cells, regulate food intake, and control inflammation. They may treat pressing major ailments such as hypertension, diabetes, obesity, heart failure, pulmonary and vascular disease. All this is within reach, we argue, if researchers from disparate disciplines in academia and industry work together. We herewith outline what needs to be done to bring about electroceuticals, and unveil a public-private research initiative and award that aim to catalyse the field.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/496159a
